ArticleJournal of cardiovascular echography
The Study on Effects of Sacubitril-Valsartan on Left Ventricular Ejection Fraction, Myocardial Biomarker, and Myocardial Remodeling in Patients with Heart Failure with Reduced Ejection Fraction.
Article in Journal of cardiovascular echography. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Left ventricular ejection fraction (LVEF) is widely used to assess cardiac function but primarily reflects volumetric changes rather than intrinsic myocardial mechanics. Sacubitril/Valsartan, an angiotensin receptor-neprilysin inhibitor, has demonstrated significant benefits in heart failure with reduced ejection fraction (HFrEF). However, its effect on LVEF and left ventricular (LV) torsional dynamics remains insufficiently explored. Materials and Methods: This prospective study enrolled 100 patients with HFrEF. Baseline evaluation included clinical history, physical examination, and laboratory parameters (body mass index, blood pressure, renal function, lipid profile, and electrolytes). Echocardiographic assessment - conventional and speckle-tracking - was performed at baseline, 3 months, and 6 months to measure LVEF, LV rotation, and torsion. Results: Participants had a mean age of 51.5 years, and 30% had diabetes. At baseline, the median LVEF was 35.5%, which improved to 40.6% at 6 months (interquartile range (IQR) =5.1; Conclusion: Sacubitril/Valsartan therapy improves LVEF and LV structural dynamics in HFrEF patients, supporting its role as a superior alternative to enalapril. These findings align with evidence of approximately 20% relative risk reduction in sudden cardiac death and heart failure-related mortality among patients with an ejection fraction <40% and elevated natriuretic peptides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.